# Schrodinger, Inc.: overview

SDGR · Nasdaq · CIK 1490978 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sdgr.md) · [Financials](/companies/sdgr/financials.md) · [Filings](/companies/sdgr/filings.md) · [Insiders](/companies/sdgr/insiders.md)

Latest reported revenue: [$58.9m](/filings/0001490978-26-000068.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001490978-26-000068).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [35.3](/filings/0001490978-25-000117.md) | [88.3 d](/filings/0001490978-26-000010.md) | [59.6](/filings/0001490978-26-000037.md) | [54.8](/filings/0001490978-26-000068.md) | [54.3](/filings/0001490978-25-000117.md) | [87.2 d](/filings/0001490978-26-000010.md) | [58.6](/filings/0001490978-26-000037.md) | [58.9](/filings/0001490978-26-000068.md) |
| Gross margin | % | [50.2%](/filings/0001490978-25-000117.md) | [72.6% d](/filings/0001490978-26-000010.md) | [52.3%](/filings/0001490978-26-000037.md) | [47.8%](/filings/0001490978-26-000068.md) | [51.6%](/filings/0001490978-25-000117.md) | [65.7% d](/filings/0001490978-26-000010.md) | [50.4%](/filings/0001490978-26-000037.md) | [55.1%](/filings/0001490978-26-000068.md) |
| Operating margin | % | [(193.9%)](/filings/0001490978-25-000117.md) | [(23.5%) d](/filings/0001490978-26-000010.md) | [(85.5%)](/filings/0001490978-26-000037.md) | [(96.6%)](/filings/0001490978-26-000068.md) | [(84.6%)](/filings/0001490978-25-000117.md) | [(19.7%) d](/filings/0001490978-26-000010.md) | [(83.3%)](/filings/0001490978-26-000037.md) | [(70.6%)](/filings/0001490978-26-000068.md) |
| Net margin | % | [(108.1%)](/filings/0001490978-25-000117.md) | [(45.5%) d](/filings/0001490978-26-000010.md) | [(100.4%)](/filings/0001490978-26-000037.md) | [(78.8%)](/filings/0001490978-26-000068.md) | [(60.4%)](/filings/0001490978-25-000117.md) | [37.3% d](/filings/0001490978-26-000010.md) | [(102.5%)](/filings/0001490978-26-000037.md) | [10.1%](/filings/0001490978-26-000068.md) |
| Diluted EPS | $ per share | [(0.52)](/filings/0001490978-25-000117.md) | not reported | [(0.82)](/filings/0001490978-26-000037.md) | [(0.59)](/filings/0001490978-26-000068.md) | [(0.45)](/filings/0001490978-25-000117.md) | not reported | [(0.81)](/filings/0001490978-26-000037.md) | [0.08](/filings/0001490978-26-000068.md) |
| Free cash flow | $m | [(34.6) d](/filings/0001490978-25-000117.md) | [(32.0) d](/filings/0001490978-26-000010.md) | [143](/filings/0001490978-26-000037.md) | [(52.5) d](/filings/0001490978-26-000068.md) | [(62.4) d](/filings/0001490978-25-000117.md) | [(16.1) d](/filings/0001490978-26-000010.md) | [(17.3)](/filings/0001490978-26-000037.md) | [(34.4) d](/filings/0001490978-26-000068.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [138](/filings/0001490978-24-000018.md) | [181](/filings/0001490978-25-000014.md) | [217](/filings/0001490978-26-000010.md) | [208](/filings/0001490978-26-000010.md) | [256](/filings/0001490978-26-000010.md) |
| Gross margin | % | [47.6%](/filings/0001490978-24-000018.md) | [55.8%](/filings/0001490978-25-000014.md) | [64.9%](/filings/0001490978-26-000010.md) | [63.6%](/filings/0001490978-26-000010.md) | [55.7%](/filings/0001490978-26-000010.md) |
| Operating margin | % | [(80.8%)](/filings/0001490978-24-000018.md) | [(81.1%)](/filings/0001490978-25-000014.md) | [(81.9%)](/filings/0001490978-26-000010.md) | [(100.8%)](/filings/0001490978-26-000010.md) | [(65.2%)](/filings/0001490978-26-000010.md) |
| Net margin | % | [(72.8%)](/filings/0001490978-24-000018.md) | [(82.4%)](/filings/0001490978-25-000014.md) | [18.8%](/filings/0001490978-26-000010.md) | [(90.2%)](/filings/0001490978-26-000010.md) | [(40.4%)](/filings/0001490978-26-000010.md) |
| Diluted EPS | $ per share | [(1.42)](/filings/0001490978-24-000018.md) | [(2.10)](/filings/0001490978-25-000014.md) | [0.54](/filings/0001490978-26-000010.md) | [(2.57)](/filings/0001490978-26-000010.md) | [(1.41)](/filings/0001490978-26-000010.md) |
| Free cash flow | $m | [(77.8)](/filings/0001490978-24-000018.md) | [(128)](/filings/0001490978-25-000014.md) | [(150)](/filings/0001490978-26-000010.md) | [(165)](/filings/0001490978-26-000010.md) | [12.5](/filings/0001490978-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sdgr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $171.0m | 10,521,724 |  | Added +843,164 |
| [GATES FOUNDATION TRUST](/funds/1166559.md) | 2026-06-30 | $113.5m | 6,981,664 |  | Unchanged |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $104.0m | 6,400,000 |  | Added +400,000 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $61.5m | 3,787,391 |  | Reduced −74,806 |
| [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $44.0m | 2,706,143 |  | Reduced −484,694 |
| [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $43.9m | 2,706,143 |  | Reduced −484,694 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $43.7m | 2,691,149 |  | Added +86,775 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $37.3m | 2,298,338 |  | Added +106,911 |
| [UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC](/funds/861177.md) | 2026-06-30 | $36.1m | 2,221,485 |  | Reduced −438,798 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $35.0m | 2,154,018 |  | Added +86,883 |

## Recent filings

[All 536 filings](/companies/sdgr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:08 ET | [10-Q](/filings/0001490978-26-000068.md) | Quarterly report, period 2026-06-30 | 0001490978-26-000068 |
| 2026-08-05 | 16:07 ET | [8-K](/filings/0001490978-26-000067.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001490978-26-000067 |
| 2026-06-29 | 16:29 ET | [8-K](/filings/0001490978-26-000059.md) | 7.01 Regulation FD disclosure | 0001490978-26-000059 |
| 2026-06-23 | 16:10 ET | [8-K](/filings/0001490978-26-000049.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001490978-26-000049 |
| 2026-06-08 | 16:22 ET | [8-K](/filings/0001490978-26-000045.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001490978-26-000045 |
| 2026-05-20 | 16:19 ET | [8-K](/filings/0001490978-26-000041.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001490978-26-000041 |
| 2026-05-05 | 16:09 ET | [10-Q](/filings/0001490978-26-000037.md) | Quarterly report, period 2026-03-31 | 0001490978-26-000037 |
| 2026-05-05 | 16:06 ET | [8-K](/filings/0001490978-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001490978-26-000036 |
| 2026-04-28 | 07:50 ET | [DEF 14A](/filings/0001490978-26-000026.md) | Proxy statement, period 2026-04-28 | 0001490978-26-000026 |
| 2026-03-12 | 16:10 ET | [8-K](/filings/0001490978-26-000013.md) | 5.02 Departure or appointment of officers or directors | 0001490978-26-000013 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001490978-26-000010.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a8c842d7-7d27-4e28-a54d-a03b2887a89b)

## About the filer

- CIK: 1490978
- Tickers: SDGR
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.